Peking University People's Hospital
Founded in 1918 as the first general hospital financed and operated by Chinese nationals, Peking University People's Hospital is a Grade A tertiary academic medical center and the Second Clinical Medical School of Peking University, home to the National Clinical Research Center for Hematologic Disease and the Peking University Institute of Hematology led by Academician Huang Xiaojun, creator of the internationally recognised Beijing Protocol for haploidentical haematopoietic stem cell transplantation, the world's most widely used haplo-HSCT system covering over 50% of global haploidentical transplantation cases.
About Peking University People's Hospital
Peking University People's Hospital (北京大å¦äººæ°‘医院, often abbreviated PKUPH) is a Grade A tertiary hospital and the Second Clinical Medical School of Peking University, affiliated with the Peking University Health Science Center. Founded on January 27, 1918 as 'Peking Central Hospital', the institution was the first modern general hospital ever founded and operated by Chinese nationals, initiated by Cao Rulin with funding from more than twenty supporters and led by its first president Dr. Wu Lien-teh (the celebrated Chinese-Malaysian physician who led the 1910-1911 Manchurian plague response). Renamed through successive eras as the Central Hospital (1946), Beijing People's Hospital (1956), the Second Affiliated Hospital of Beijing Medical College (1958), and finally Peking University People's Hospital in 2000 following the merger of Beijing Medical University into Peking University, the hospital was approved as a Grade A tertiary hospital by the Ministry of Health on March 26, 1994. Its 2013 reform programme became a featured case study at Harvard Business Publishing.
Today PKUPH operates three campuses in Beijing — the Xizhimen main campus at No. 11 Xizhimen South Street in Xicheng District (founded 1991, 690 beds), the Qinghe Campus in Haidian District (opened 2014, 75,000 square metres), and the Tongzhou Campus in eastern Beijing (opened 2021, 800 beds with dedicated centres for trauma emergency, obstetrics and gynecology, and tumour radiotherapy and chemotherapy) — plus expanding national capacity through the Qingdao Hospital (2021), Shijiazhuang Hospital (2022), and the major new Xiong'an branch in Hebei (groundbreaking 2023) which is planned to function as a national medical centre with 1,000-bed capacity. The institution employs approximately 1,300 physicians, 2,466 nurses and 1,076 supporting staff across its Beijing campuses, with a combined capacity of more than 2,600 beds. Annual activity exceeds 153,580 inpatient admissions, 3,378,525 outpatient visits and 66,030 surgical procedures. PKUPH was authorised in 2019 to host the National Clinical Research Center for Hematologic Disease and the National Center for Trauma Medicine, and is China's first HIMSS EMRAM Stage 7 certified hospital.
PKUPH's most internationally distinguished programme is haematology, delivered through the Peking University Institute of Hematology, the National Clinical Research Center for Hematologic Disease and the Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, led by Academician Huang Xiaojun of the Chinese Academy of Engineering. Since 2004, Professor Huang's team has developed and refined the Beijing Protocol — a G-CSF/ATG-based non-T-cell-depleted haploidentical haematopoietic stem cell transplantation system — which raised three-year survival in haploidentical leukaemia transplantation from approximately 20 per cent to approximately 70 per cent, was officially named by the International Society for Blood and Marrow Transplantation in 2016, and is now the world's most widely used haplo-HSCT system, adopted by more than 190 transplant centres across China and extended internationally to centres in South Korea, Italy, France and Israel. By the end of 2021, PKUPH had become the world's largest centre for allogeneic and haploidentical transplantation, with the Beijing Protocol covering over 50 per cent of all global haploidentical transplantation cases. Professor Huang received the CIBMTR Distinguished Service Award at the 2024 Tandem Meetings in San Antonio for his contribution to international haematology. Beyond haematology, PKUPH leads China in lung cancer surgery (95 per cent minimally invasive, with reported 91.3 per cent five-year survival in published series), pioneered the 'Tube-Free Esophagectomy' technique for esophageal cancer surgery, and operates one of China's leading trauma centres.
CancerFax works with international and Indian families considering Peking University People's Hospital primarily for haematological malignancies and inherited haematological disorders requiring allogeneic or haploidentical HSCT, where PKUPH offers genuinely world-leading clinical capability. We also coordinate access for other oncologic indications including minimally invasive lung cancer surgery and esophageal cancer surgery. Within the CancerFax haematology hospital portfolio in China, PKUPH sits alongside Lu Daopei Hospital in Beijing-Yanda (Asia's highest cumulative CAR-T volume and an EBMT member) and the Institute of Hematology and Blood Diseases Hospital in Tianjin (CAMS-affiliated national tertiary blood hospital with the largest haematology clinical trial portfolio in China), and we will openly compare these three options based on the specific clinical situation. PKUPH operates an English-language website at english.pkuph.cn, but CancerFax provides the full coordination layer including accredited record translation, Chinese visa support documentation, in-person interpreter support, transparent cost estimates against international alternatives, and accommodation guidance near the Xizhimen or Tongzhou campuses. CancerFax charges patients nothing for this navigation.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Beijing (Xicheng District main campus, plus Haidian Qinghe and Tongzhou campuses) |
| Established | January 27, 1918 (oldest Chinese-founded general hospital in China) |
| Hospital Type | Grade A Tertiary Public Hospital · Second Clinical Medical School of Peking University · Affiliated with Peking University Health Science Center |
| Accreditation | Grade A Tertiary Hospital (since March 26, 1994) · HIMSS EMRAM Stage 7 (China's first) · National Clinical Research Center for Hematologic Disease (since 2019) · National Center for Trauma Medicine (since 2019) · ⚠VERIFY: JCI accreditation status not publicly confirmed on the hospital's English site |
| Beds | Over 2,600 beds across three Beijing campuses (Xizhimen 690 beds, Tongzhou 800 beds, Qinghe), plus expanding national capacity in Qingdao, Shijiazhuang and Xiong'an |
| Annual Patient Activity | Approximately 3.38 million outpatient visits, 153,580 inpatient admissions and 66,030 surgical procedures per year in Beijing |
| Research Focus | Beijing Protocol haploidentical HSCT (Peking University Institute of Hematology, led by Academician Huang Xiaojun); acute leukaemia, chronic myeloid leukaemia, myeloma, lymphoma; trauma medicine; minimally invasive lung and esophageal cancer surgery; cellular therapy; AML drug resistance research |
Why Patients Choose Peking University People's Hospital
Peking University People's Hospital is the world's largest centre for allogeneic and haploidentical haematopoietic stem cell transplantation, the academic home of the Beijing Protocol for haplo-HSCT, and the host institution for China's National Clinical Research Center for Hematologic Disease, with additional national-leading programmes in trauma medicine, minimally invasive lung cancer surgery and esophageal cancer surgery.
Cancer Specialties and Clinical Departments
Peking University People's Hospital provides comprehensive academic medical care across the full spectrum of medicine, with particular international leadership in haematological malignancies and haematopoietic stem cell transplantation through the Peking University Institute of Hematology, alongside major programmes in lung, esophageal and gastrointestinal cancers.
Advanced Treatment Capabilities
Key Specialists at Peking University People's Hospital
Peking University People's Hospital employs approximately 1,300 physicians, 2,466 nurses and 1,076 supporting staff across its three Beijing campuses, training more than 1,000 students of various types and nearly 1,800 visiting doctors and resident physicians each year as the Second Clinical Medical School of Peking University. The hospital's most internationally celebrated faculty member is Academician Huang Xiaojun of the Chinese Academy of Engineering, President of the Peking University Institute of Hematology, Director of the National Clinical Research Center for Hematologic Disease and recipient of the 2024 CIBMTR Distinguished Service Award for his establishment of the Beijing Protocol for haploidentical haematopoietic stem cell transplantation. Professor Huang's research group includes senior haematologists and transplant physicians who collectively form the largest active allogeneic and haploidentical HSCT team globally, supported by Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation and the Peking-Tsinghua Center for Life Sciences.
Patient pathways at PKUPH are organised through disease-specific multidisciplinary teams: complex leukaemia and HSCT cases are managed jointly by haematology, transplantation and cellular immunotherapy specialists; minimally invasive thoracic cancer cases by the Thoracic Surgery Department; and complex esophageal cancer cases by the Department of Thoracic Surgery using the institution's pioneering tube-free esophagectomy technique. Patients seeking a specific physician consultation or a focused multidisciplinary second opinion can submit their request through CancerFax. We work with the appropriate PKUPH department on the patient's behalf to confirm in advance which named senior consultant will be assigned to the case, and will tell you openly if a different centre, such as Lu Daopei Hospital for high-volume CAR-T or specific novel cellular therapy constructs, or the Institute of Hematology and Blood Diseases Hospital in Tianjin for clinical trial-led care, would serve your specific case more appropriately.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
Clinical Infrastructure and Treatment Technology
Peking University People's Hospital operates more than 2,600 beds across three Beijing campuses with integrated electronic medical records (China's first HIMSS EMRAM Stage 7 hospital), the National Clinical Research Center for Hematologic Disease infrastructure, the Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation and a dedicated tumour radiotherapy and chemotherapy centre at the Tongzhou Campus.
- World's largest allogeneic and haploidentical HSCT programme by volume, delivering the Beijing Protocol developed by Academician Huang Xiaojun's team since 2004
- Matched related, matched unrelated and haploidentical donor protocols, with the Beijing Protocol covering over 50% of global haplo-HSCT cases
- Autologous stem cell transplantation for multiple myeloma, lymphoma and selected solid tumour indications
- Multi-parameter flow cytometry for immunophenotyping and measurable residual disease (MRD) monitoring
- Chromosome FISH detection and real-time quantitative PCR for haematological malignancy genetic profiling
- National Clinical Research Center for Hematologic Disease and Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation infrastructure
- Minimally invasive thoracic oncology: 95% of lung cancer surgeries performed minimally invasively with reported 91.3% five-year survival in published series
- Tube-Free Esophagectomy technique pioneered at PKUPH, allowing oral intake within 24 hours of esophageal cancer surgery in selected patients
- Comprehensive surgical oncology across general, gastrointestinal, urological, gynecologic, head and neck and thoracic specialties
- Tumour Radiotherapy and Chemotherapy Center at the Tongzhou Campus; advanced photon radiotherapy including IMRT, IGRT and stereotactic radiosurgery (âš VERIFY: specific equipment with the hospital)
- Diagnostic imaging across MRI, CT, PET-CT and ultrasound at all three Beijing campuses
- China's first HIMSS EMRAM Stage 7 certified hospital, with first 5G-and-drone blood delivery system for trauma response
International Patient Support at Peking University People's Hospital
Peking University People's Hospital operates an English-language website at english.pkuph.cn and receives international patients through Beijing's network of academic medical centres. The hospital's primary clinical operating language is Mandarin Chinese, and CancerFax provides the comprehensive coordination layer that international families need to navigate consultation, admission, treatment and follow-up.
What to Prepare Before Traveling
- arrow_rightShare complete haematology and oncology records including bone marrow biopsy and aspirate findings, flow cytometry and cytogenetics, recent imaging (CT, PET-CT, MRI), molecular and minimal residual disease (MRD) data, prior chemotherapy or transplant treatment summaries, immunisation records and a current medication list (in English or Chinese) with CancerFax at least two to three weeks before the planned consultation.
- arrow_rightApply for an appropriate Chinese visa (M for medical or L for tourist) at your nearest Chinese consulate. PKUPH can issue an official invitation letter for the patient and accompanying family members; many South and Southeast Asian countries also have e-visa or visa-on-arrival options for short stays in mainland China.
- arrow_rightPlan travel via Beijing Capital International Airport (PEK) or Beijing Daxing International Airport (PKX). The Xizhimen main campus is centrally located in Xicheng District with metro access via Beijing Metro Line 4 and Line 2. Allow at least four to six weeks for an initial haematology evaluation, induction therapy and HSCT donor workup, with longer stays of several months required for allogeneic transplantation including the haploidentical pre-transplant conditioning, transplant and acute post-transplant recovery.
Peking University People's Hospital can be reached through its official English-language site at english.pkuph.cn. CancerFax coordinates all submissions, translation, visa and travel arrangements on the patient's behalf, manages comparison with Lu Daopei Hospital, IHBDH Tianjin and other haematology centres where useful, and remains the single point of contact through treatment and follow-up at no cost to the patient.
Patient Facilities and Accommodation at Peking University People's Hospital
Peking University People's Hospital operates three Beijing campuses with integrated inpatient care, on-site pharmacy, transfusion services, dedicated transplant wards including HEPA-filtered laminar flow rooms for the Beijing Protocol HSCT programme, and multidisciplinary support services across the Xizhimen main campus, Qinghe Campus and Tongzhou Campus.
Family members accompanying international HSCT or chemotherapy patients can stay at hotels in Xicheng District near the Xizhimen main campus (the most central location with the widest accommodation choice) or near the Tongzhou or Qinghe campuses as appropriate for the assigned treatment site. For HSCT cases requiring extended family stays of several months, CancerFax can help plan budget-conscious longer-term apartment options in Beijing.
How to Reach Peking University People's Hospital
Peking University People's Hospital operates three Beijing campuses: the Xizhimen main campus in central Xicheng District, the Qinghe Campus in northern Haidian District, and the Tongzhou Campus in eastern Beijing. All are accessible from Beijing's two international airports via expressway and Beijing Metro.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Peking University People's Hospital — Patient Questions Answered
CancerFax acts as your single coordinator for the entire PKUPH journey. You begin by sharing your medical records, including pathology and bone marrow biopsy and aspirate findings, flow cytometry, cytogenetics, recent imaging, prior chemotherapy or transplant treatment summaries through our secure intake. Our clinical team reviews your case and identifies whether PKUPH is the right haematology and HSCT centre for your specific diagnosis, particularly for patients potentially eligible for the Beijing Protocol haploidentical transplantation (where a fully matched related or unrelated donor is not available). We then submit your case to the Peking University Institute of Hematology and confirm in advance which named senior consultant will see you.
Once your consultation is confirmed, CancerFax prepares your full pre-travel pack: PKUPH's official cost estimate translated into English (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited translation of your home-country reports into Chinese, in-person interpreter support during consultations and ward rounds, accommodation guidance near the assigned campus (Xizhimen, Qinghe or Tongzhou), and travel logistics via Beijing's international airports. We remain your single point of contact through admission, transplantation or chemotherapy, discharge and post-treatment follow-up. Where useful, we will openly compare PKUPH alongside parallel pathways at Lu Daopei Hospital (Beijing-Yanda, Asia's highest-volume CAR-T centre and EBMT member) and the Institute of Hematology and Blood Diseases Hospital in Tianjin (CAMS-affiliated national tertiary blood hospital). There is no fee to the patient for any of this coordination.
The Beijing Protocol is a non-T-cell-depleted haploidentical haematopoietic stem cell transplantation system developed since 2004 by Academician Huang Xiaojun of the Chinese Academy of Engineering at the Peking University Institute of Hematology at PKUPH. It uses a granulocyte colony-stimulating factor (G-CSF) and antithymocyte globulin (ATG) based regimen rather than T-cell depletion, and has fundamentally changed what 'eligible for transplant' means for leukaemia patients without a fully matched related or unrelated donor. Before the Beijing Protocol, the three-year survival rate for haploidentical leukaemia transplantation was approximately 20 per cent; the Beijing Protocol raised this to approximately 70 per cent. The protocol was officially named by the International Society for Blood and Marrow Transplantation in 2016, is used at more than 190 transplant centres across China, has been extended internationally to centres in South Korea, Italy, France and Israel, and covers over 50 per cent of all global haploidentical transplantation cases. For patients from countries with shallow unrelated donor registries (which includes many countries in South Asia, Southeast Asia and parts of Africa), the Beijing Protocol at PKUPH may genuinely be the difference between being transplant-eligible and not. CancerFax assesses Beijing Protocol eligibility from your records before any travel commitment.
All three institutions are world-class Chinese haematology centres, but they serve subtly different clinical positioning. PKUPH is the academic flagship for haploidentical haematopoietic stem cell transplantation through the Beijing Protocol, with the world's largest cumulative volume of allogeneic and haploidentical transplantation and the host institution for the National Clinical Research Center for Hematologic Disease. Lu Daopei Hospital in Beijing-Yanda is Asia's highest cumulative CAR T-cell therapy centre, an EBMT member institution, and has pioneered specific novel CAR-T constructs including NS7CAR-T (CD7-targeting) and dual-target CAR-T. The Institute of Hematology and Blood Diseases Hospital in Tianjin (IHBDH) is the only national tertiary specialised hospital dedicated entirely to haematological diseases, jointly affiliated with the Chinese Academy of Medical Sciences and Peking Union Medical College, and runs the largest haematology clinical trial portfolio in China with 460-plus active studies. CancerFax will not recommend any one of these by default; we match the specific case to the institution most likely to provide the best clinical fit, often discussing two or three in parallel before the family commits to travel.
Yes. PKUPH accepts foreign-language medical records and can provide a written opinion based on your submission before any travel commitment, particularly for haematology and HSCT cases where the entire Beijing Protocol eligibility assessment can largely be made from records alone (bone marrow biopsy and aspirate findings, flow cytometry, cytogenetics, prior treatment history, donor availability information for related family members). CancerFax facilitates this submission, coordinates accredited Chinese-English translation of your reports, follows up on your behalf and helps you understand the resulting opinion, including how it compares with treatment plans from Lu Daopei Hospital, IHBDH Tianjin and international haematology centres in South Korea, Singapore, India and the United States. A remote opinion is the most efficient first step for haematology cases because transplant or CAR-T eligibility depends on a comprehensive review of records that can largely be assessed before any in-person evaluation.
As a Grade A tertiary Chinese public academic hospital under Peking University, PKUPH offers haematology and HSCT treatment at significantly lower cost than equivalent care at private international hospitals or hospitals in the United States, the United Kingdom or Singapore. Allogeneic haematopoietic stem cell transplantation at PKUPH (including the Beijing Protocol haploidentical pathway) is typically 50 to 70 per cent less expensive than the equivalent procedure in Western hospitals. Costs are broadly comparable with other major Chinese public haematology centres including Lu Daopei Hospital and IHBDH Tianjin, though specific pricing depends on the protocol, donor type, conditioning regimen and complication contingency. CancerFax shares PKUPH's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with Lu Daopei, IHBDH and international haematology centres before any decision is made. We always recommend asking for a 'complication contingency' estimate alongside the base transplant cost, because post-transplant complications such as severe infection or chronic GVHD can add meaningfully to the total.
Send Your Medical Reports to Peking University People's Hospital via CancerFax
CancerFax reviews your records, identifies whether PKUPH (with the Beijing Protocol haploidentical HSCT pathway), Lu Daopei Hospital, or IHBDH Tianjin is the right haematology centre for your case, and coordinates your consultation or remote second opinion in Beijing at no cost, with no obligation, and with full medical confidentiality throughout.